GlassScriptPhysician profile
Susan L Johnson
NPI 1679581227
$2,702.45
in general payments reported to CMS, 2019-2025
24 companies · $17.05 in 2025
The $17.05 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $799 · 2021: $72.34 · 2022: $421 · 2023: $20.00 · 2025: $17.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $20.00 · Food and Beverage: $17.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $20.00 |
| Food and Beverage | $17.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $487.10 | 2019-2025 | Ozempic |
| Amgen INC. | $444.60 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $334.27 | 2019-2020 | |
| Abbvie INC. | $236.00 | 2019-2022 | |
| Allergan, INC. | $225.66 | 2019 | |
| Glaxosmithkline, LLC. | $181.98 | 2019-2020 | |
| Lilly USA, LLC | $143.77 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $93.02 | 2019-2020 | |
| Pfizer INC. | $82.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.05 | 2019-2022 | |
| Genentech USA, INC. | $66.32 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $48.44 | 2019-2020 | |
| Amarin Pharma, INC. | $46.71 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $38.08 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $37.61 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.40 | 2020 | |
| Upsher-Smith Laboratories LLC | $20.10 | 2020 | |
| Mannkind Corporation | $20.00 | 2023 | Afrezza |
| Sanofi Pasteur INC. | $19.48 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.75 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.40 | 2019 | |
| Astellas Pharma US INC | $12.64 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.62 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.